drugset / Trial / NCT06855823
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.
Timeline
- Start
- 2025-01-14
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 3 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |